Pralsetinib showed robust and durable clinical activity with a well-tolerated safety profile in Chinese patients with RET fusion-positive non–small cell lung cancer (NSCLC) The most common grade 3/4 treatment-related adverse events in 68 patients were anemia (35.3%) and decreased neutrophil count (33.8%) As of March 4, 2022 (data cutoff), a confirmed objective response was observed in 22 (66.7%) of 33 pretreated patients, including 1 (3.0%) complete response and 21 (63.6%) partial responses . Median progression-free survival was 11 .7 months (95% CI, 8.9–not estimable)